A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis

Arthritis and Rheumatology

Volumn 69, Issue 4, 2017, Pages 837-845

  Langford, Carol A ^a   Cuthbertson, David ^b   Ytterberg, Steven R ^c   Khalidi, Nader ^d   Monach, Paul A ^e   Carette, Simon ^f   Seo, Philip ^g   Moreland, Larry W ^h   Weisman, Michael ⁱ   Koening, Curry L ^j   Sreih, Antoine G ^k   Spiera, Robert ^l   McAlear, Carol A ^k   Warrington, Kenneth J ^c   Pagnoux, Christian ^f   McKinnon, Kathleen ^h   Forbess, Lindsy J ⁱ   Hoffman, Gary S ^a   Borchin, Renée ^b   Krischer, Jeffrey P ^b   Merkel, Peter A ^k   Hajj Ali, Rula ^m   Tuthill, Katherine ^m   Gartner, Kathleen ^m   Madden, Leah ^m   Matteson, Eric L ^m   Kermani, Tanaz ^m   Jaquith, Jane ^m   Amudala, Naomi ^m   Clark Cotton, Manuella ^m   Messier, Sandra ^m   Farquharson, Julia ^m   Jagadeesh, Samyukta ^m   McBride, Dawn ^m   Venuturupalli, Swamy ^m   Wallace, Daniel ^m   Phan, Richard ^m   Verde, Nadia ^m   Salinas, Denise ^m   Godina, Jennifer ^m   Davids, Morgana ^m   Udeh, Uzunma ^m   Sejismundo, Lourdes ^m   Harris, Jennifer ^m   more..

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c MAYO CLINIC   (United States)

^d ST JOSEPH S HOSPITAL   (Canada)

^e BOSTON UNIVERSITY   (United States)

^f MOUNT SINAI HOSPITAL   (Canada)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h UNIVERSITY OF PITTSBURGH   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j UNIVERSITY OF UTAH   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l HOSPITAL FOR SPECIAL SURGERY   (United States)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; PLACEBO; PREDNISONE;

ADULT; AGED; ARTICLE; BRANCH RETINAL ARTERY OCCLUSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DISEASE DURATION; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; ELECTROLYTE DISTURBANCE; ENDOMETRIUM CARCINOMA; FAINTNESS; FEMALE; FOLLOW UP; GIANT CELL ARTERITIS; HEMATOMA; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MELENA; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARTIAL BLINDNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; REMISSION; RETINA DETACHMENT; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; URINARY TRACT INFECTION; WITHDRAWAL SYNDROME; CLINICAL TRIAL; VERY ELDERLY;

ABATACEPT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; GIANT CELL ARTERITIS; HUMANS; MALE; MIDDLE AGED;

EID: 85014388193     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40044     Document Type: Article

References (30)

1. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003;139:505–15.
2. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med 2014;371:50–7.
3. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261–71.
4. Salvarani C, Crowson CS, O'Fallon WM, Hunder GG, Gabriel SE. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum 2004;51:264–8.
5. Birkhead NC, Wagener HP, Shick RM. Treatment of temporal arteritis with adrenal corticosteroids: results in fifty-five cases in which lesion was proved at biopsy. J Am Med Assoc 1957;163:821–7.
6. Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology 1993;100:550–5.
7. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703–8.
8. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309–18.
9. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003;349:160–9.
10. Weyand CM, Ma-Krupa W, Pryshchep O, Groschel S, Bernardino R, Goronzy JJ. Vascular dendritic cells in giant cell arteritis. Ann N Y Acad Sci 2005;1062:195–208.
11. Brack A, Geisler A, Martinez-Taboada VM, Younge BR, Goronzy JJ, Weyand CM. Giant cell vasculitis is a T cell-dependent disease. Mol Med 1997;3:530–43.
12. Weyand CM, Goronzy JJ. Giant cell arteritis as an antigen-driven disease. Rheum Dis Clin North Am 1995;21:1027–39.
13. Bluestone JA, St.Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 2006;24:233–8.
14. Cron RQ. A signal achievement in the treatment of arthritis [editorial]. Arthritis Rheum 2005;52:2229–32.
15. Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB. Structural analysis of CTLA-4 function in vivo. J Immunol 2000;164:5319–27.
16. Kremer JM, Westhovens R, Leon M, di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907–15.
17. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005;353:1114–23.
18. Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73:86–94.
19. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122–8.
20. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:106–14.
21. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007;146:621–30.
22. Seror R, Baron G, Hachulla E, Debandt M, Larroche C, Puéchal X, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis 2014;73:2074–81.
23. Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001;19:495–501.
24. Mahr AD, Jover JA, Spiera RF, Hernández-García C, Fernández-Gutiérrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007;56:2789–97.
25. Kermani TA, Warrington KJ, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al. Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J Rheumatol 2015;42:1213–7.
26. Direskeneli H, Aydin SZ, Kermani TA, Matteson EL, Boers M, Herlyn K, et al. Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J Rheumatol 2011;38:1471–9.
27. Aydin SZ, Direskeneli H, Sreih A, Alibaz-Oner F, Gul A, Kamali S, et al. Update on outcome measure development for large vessel vasculitis:30 report from OMERACT 12. J Rheumatol 2015;42:2465–9.
28. Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016;387:1921–7.
29. Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 2012;64:1720–9.
30. Unizony SH, Dasgupta B, Fisheleva E, Rowell L, Schett G, Spiera R, et al. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol 2013;2013:912562.